 |
 Video: What is a Stock Split?
|
|
|
| Lyra Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of therapies for the treatment of patients with chronic rhinosinusitis (CRS). Co.'s technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Co.'s product candidates, LYR-210, which is designed to treat CRS patients both with and without nasal polyps who have failed previous medical management and have not undergone endoscopic sinus surgery; and LYR-220, which is also designed to utilize mometasone furoate, and employs a larger matrix designed for patients whose nasal cavity is enlarged due to sinus surgery. According to our Lyra Therapeutics stock split history records, Lyra Therapeutics has had 0 splits. | |
|
Lyra Therapeutics (LYRA) has 0 splits in our Lyra Therapeutics stock split history database.
Looking at the Lyra Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lyra Therapeutics shares, starting with a $10,000 purchase of LYRA, presented on a split-history-adjusted basis factoring in the complete Lyra Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
05/04/2020 |
|
| End date: |
04/25/2024 |
|
| Start price/share: |
$17.78 |
|
| End price/share: |
$5.17 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-70.92% |
|
| Average Annual Total Return: |
-26.69% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,908.09 |
|
| Years: |
3.98 |
|
|
|
|
|
